Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Non-Current Assets: 2024-2025

Historic Non-Current Assets for Kura Oncology (KURA) over the last 2 years, with Sep 2025 value amounting to $28.7 million.

  • Kura Oncology's Non-Current Assets rose 83.53% to $28.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.7 million, marking a year-over-year increase of 83.53%. This contributed to the annual value of $15.3 million for FY2024, which is N/A change from last year.
  • As of Q3 2025, Kura Oncology's Non-Current Assets stood at $28.7 million, which was up 28.49% from $22.4 million recorded in Q2 2025.
  • Kura Oncology's 5-year Non-Current Assets high stood at $28.7 million for Q3 2025, and its period low was $15.3 million during Q4 2024.
  • Its 2-year average for Non-Current Assets is $19.0 million, with a median of $16.1 million in 2024.
  • Data for Kura Oncology's Non-Current Assets shows a peak YoY surged of 83.53% (in 2025) over the last 5 years.
  • Quarterly analysis of 2 years shows Kura Oncology's Non-Current Assets stood at $15.3 million in 2024, then surged by 83.53% to $28.7 million in 2025.
  • Its Non-Current Assets stands at $28.7 million for Q3 2025, versus $22.4 million for Q2 2025 and $19.6 million for Q1 2025.